Accendra Health, Inc.（ACH）財務資料ACHAccendra Health, Inc.

Accendra Health, Inc. (ACH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diabetes, accounting for 32.4% of total sales, equivalent to $198.82M. Other significant revenue streams include Sleep therapy and Home respiratory therapy. Understanding this composition is critical for investors evaluating how ACH navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Accendra Health, Inc. maintains a gross margin of 38.22%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.49%, while the net margin is -14.52%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ACH converts its operational activities into shareholder value.

In the context of the broader market, ACH competes directly with industry leaders such as BDMD and ARAY. With a market capitalization of $19.64M, it holds a significant position in the sector. When comparing efficiency, ACH's gross margin of 38.22% stands against BDMD's 86.97% and ARAY's 34.34%. Such benchmarking helps identify whether Accendra Health, Inc. is trading at a premium or discount relative to its financial performance.

Accendra Health has reported a net loss of $89.1 million in Q2 2026, with a gross margin that has decreased to 38.22%. The company's total revenue for Q2 2026 was $613.2 million, down 10.1% from the previous year, reflecting ongoing challenges in maintaining revenue stability.